PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer.

Abstract To investigate the diagnostic value of urothelial carcinoma-associated 1 as a urine biomarker in urinary bladder cancer patients by performing a comprehensive meta-analysis. A comprehensive literature search was conducted by the databases PubMed, Embase, Cochrane Library, China Knowledge Resource Integrated, and Web of Science. The quality of eligible studies was scored with the Quality Assessment of Diagnostic Accuracy Studies. The bivariate meta-analysis model was used to pool the sensitivity, specificity, likelihood ratio, and diagnostic odds ratio. Receiver operating characteristic curves and hierarchical summary receiver operating characteristic models were employed to check the overall test performance in this meta-analysis. Seven publications involving 678 patients and 563 controls were included in this meta-analysis. The pooled sensitivity was 0.84 (95% confidence interval: 0.80-0.88), specificity was 0.87 (95% confidence interval: 0.75-0.94), positive likelihood ratio was 6.5 (95% confidence interval: 3.10-13.62), negative likelihood ratio was 0.18 (95% confidence interval: 0.13-0.25), and diagnostic odds ratio was 36 (95% confidence interval: 13-99). The area under the summary receiver operating characteristic curve was 0.89 (95% confidence interval: 0.86-0.91). Our results indicated that urothelial carcinoma-associated 1 was a potential diagnostic biomarker with good specificity and sensitivity in urinary bladder cancer. Further prospective studies with larger cohorts are necessary to evaluate the diagnostic accuracy of urothelial carcinoma-associated 1 for urinary bladder cancer.
PMID
Related Publications

Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.

Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.

Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.

Urinary protein biomarker panel for the detection of recurrent bladder cancer.

Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay.

Authors

Mayor MeshTerms
Keywords

Bladder cancer

biomarker

diagnosis

long non-coding RNA

urothelial carcinoma–associated 1

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28639914
OWN - NLM
STAT- MEDLINE
DA  - 20170622
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for
      the diagnosis of urinary bladder cancer.
PG  - 1010428317709990
LID - 10.1177/1010428317709990 [doi]
AB  - To investigate the diagnostic value of urothelial carcinoma-associated 1 as a
      urine biomarker in urinary bladder cancer patients by performing a comprehensive 
      meta-analysis. A comprehensive literature search was conducted by the databases
      PubMed, Embase, Cochrane Library, China Knowledge Resource Integrated, and Web of
      Science. The quality of eligible studies was scored with the Quality Assessment
      of Diagnostic Accuracy Studies. The bivariate meta-analysis model was used to
      pool the sensitivity, specificity, likelihood ratio, and diagnostic odds ratio.
      Receiver operating characteristic curves and hierarchical summary receiver
      operating characteristic models were employed to check the overall test
      performance in this meta-analysis. Seven publications involving 678 patients and 
      563 controls were included in this meta-analysis. The pooled sensitivity was 0.84
      (95% confidence interval: 0.80-0.88), specificity was 0.87 (95% confidence
      interval: 0.75-0.94), positive likelihood ratio was 6.5 (95% confidence interval:
      3.10-13.62), negative likelihood ratio was 0.18 (95% confidence interval:
      0.13-0.25), and diagnostic odds ratio was 36 (95% confidence interval: 13-99).
      The area under the summary receiver operating characteristic curve was 0.89 (95% 
      confidence interval: 0.86-0.91). Our results indicated that urothelial
      carcinoma-associated 1 was a potential diagnostic biomarker with good specificity
      and sensitivity in urinary bladder cancer. Further prospective studies with
      larger cohorts are necessary to evaluate the diagnostic accuracy of urothelial
      carcinoma-associated 1 for urinary bladder cancer.
FAU - Wang, Zichun
AU  - Wang Z
AD  - 1 Department of Urology, The First Affiliated Hospital of Harbin Medical
      University, Harbin, China.
FAU - Wang, Xiaoxiong
AU  - Wang X
AD  - 2 Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical
      University, Harbin, China.
FAU - Zhang, Daming
AU  - Zhang D
AD  - 2 Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical
      University, Harbin, China.
AD  - 3 Department of Pharmacology, Harbin Medical University, Harbin, China.
FAU - Yu, Yongchun
AU  - Yu Y
AD  - 1 Department of Urology, The First Affiliated Hospital of Harbin Medical
      University, Harbin, China.
FAU - Cai, Licheng
AU  - Cai L
AD  - 1 Department of Urology, The First Affiliated Hospital of Harbin Medical
      University, Harbin, China.
FAU - Zhang, Cheng
AU  - Zhang C
AD  - 1 Department of Urology, The First Affiliated Hospital of Harbin Medical
      University, Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (UCA1 RNA, human)
SB  - IM
MH  - Biomarkers, Tumor/*urine
MH  - Carcinoma, Transitional Cell/pathology/*urine
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Prognosis
MH  - RNA, Long Noncoding/*urine
MH  - Urinary Bladder Neoplasms/pathology/*urine
OTO - NOTNLM
OT  - Bladder cancer
OT  - biomarker
OT  - diagnosis
OT  - long non-coding RNA
OT  - urothelial carcinoma-associated 1
EDAT- 2017/06/24 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/23 06:00
AID - 10.1177/1010428317709990 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317709990. doi: 10.1177/1010428317709990.